Related Experiment Video
Updated: Mar 2, 2026

Imaging CD4 T Cell Interstitial Migration in the Inflamed Dermis
Published on: March 25, 2016
Chemokine profiles of interstitial pneumonia in patients with dermatomyositis: a case control study
Katsuhiro Oda1, Takuya Kotani2, Tohru Takeuchi1
1Department of Internal Medicine (I), Osaka Medical College, Takatsuki, Osaka, Japan.
Abstract:
Chemokines play an important role in the pathophysiology of dermatomyositis (DM) with interstitial pneumonia (IP). However, the relation between chemokines and the disease activity or prognosis of DM-IP has not been elucidated. We evaluated the serum C-C motif chemokine ligand (CCL) 2, Th1 chemokines (C-X-C motif chemokine ligand [CXCL] 9, CXCL10, CXCL11), and Th2 chemokine (CCL17) profiles of 30 patients, and examined the relation between these chemokines and the disease activity or prognosis of DM-IP. Initial serum CCL2 level was higher in the death group (P = 0.007). To determine the cut-off points effective as poor prognostic factors of DM-IP, ROC curve analysis was carried out on initial serum CCL2 level. The value that maximized the area under the ROC curve was 894 pg/mL (sensitivity: 100%, specificity: 70.8%). Serum CCL2, CXCL9, CXCL10, and CXCL11 levels were lower at 2 weeks after treatment initiation than before treatment. Serum CCL2, CXCL10, and CXCL11 levels at 2 weeks after treatment initiation were higher in the death group. Serum levels of chemokines such as CCL2, CXCL10, and CXCL11 may be possible biomarkers of disease activity and prognosis in DM-IP, and serum CCL2 level may be useful when deciding initial treatment.
Insights
Serum C-C motif chemokine ligand 2 (CCL2) levels predict prognosis in dermatomyositis with interstitial pneumonia (DM-IP). Higher initial CCL2 levels indicate a poorer prognosis, and CCL2 may guide initial treatment decisions for DM-IP patients.
Area of Science:
- Immunology
- Pulmonology
- Rheumatology
Background:
- Chemokines are implicated in the pathology of dermatomyositis with interstitial pneumonia (DM-IP).
- The prognostic significance of chemokine profiles in DM-IP remains unclear.
Purpose of the Study:
- To investigate the relationship between serum chemokine levels and disease activity or prognosis in DM-IP.
- To identify potential chemokine biomarkers for predicting outcomes in DM-IP.
Main Methods:
- Serum levels of CCL2, CXCL9, CXCL10, CXCL11, and CCL17 were measured in 30 DM-IP patients.
- Correlation analysis was performed between chemokine levels, disease activity, and prognosis.
- Receiver operating characteristic (ROC) curve analysis determined prognostic cut-off points for CCL2.
Main Results:
- Initial serum CCL2 levels were significantly higher in patients who died (P=0.007).
- A CCL2 level of 894 pg/mL was identified as a poor prognostic factor (sensitivity: 100%, specificity: 70.8%).
- Chemokine levels (CCL2, CXCL10, CXCL11) at 2 weeks post-treatment were higher in the non-survivor group.
Conclusions:
- Serum CCL2, CXCL10, and CXCL11 levels may serve as biomarkers for disease activity and prognosis in DM-IP.
- Initial serum CCL2 levels could aid in guiding treatment decisions for DM-IP.
More Related Videos
10:21Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
10:55Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy
Published on: October 31, 2025